{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:01:44Z","timestamp":1762876904488,"version":"3.45.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272855","8220160045"],"award-info":[{"award-number":["82272855","8220160045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-025-01053-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:56:47Z","timestamp":1762873007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Whole-exome sequencing of FFPE samples reveals mutations associated with Luminal A breast cancer recurrence"],"prefix":"10.1186","volume":"25","author":[{"given":"Kezhen","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"1130","key":"1053_CR1","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.","journal-title":"Br J Radiol"},{"issue":"1","key":"1053_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1053_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1053_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/cac2.12207","volume":"41","author":"S Lei","year":"2021","unstructured":"Lei S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021;41(11):1183\u201394.","journal-title":"Cancer Commun (Lond)"},{"key":"1053_CR5","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, et al. Subtypes of breast cancer. In: Mayrovitz HN, editor Breast Cancer. Brisbane (AU). 2022","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"1","key":"1053_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","volume":"3","author":"KS Johnson","year":"2021","unstructured":"Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: A review for breast radiologists. J Breast Imaging. 2021;3(1):12\u201324.","journal-title":"J Breast Imaging"},{"issue":"10","key":"1053_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","volume":"21","author":"R Haque","year":"2012","unstructured":"Haque R, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1848\u201355.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1053_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1186\/s12885-021-08642-6","volume":"21","author":"Y Li","year":"2021","unstructured":"Li Y, Ma L. Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer. BMC Cancer. 2021;21(1):965.","journal-title":"BMC Cancer"},{"issue":"10","key":"1053_CR9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1053_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1053_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40291-021-00525-7","volume":"25","author":"B Pellegrino","year":"2021","unstructured":"Pellegrino B, et al. Luminal breast cancer: risk of recurrence and Tumor-Associated immune suppression. Mol Diagn Ther. 2021;25(4):409\u201324.","journal-title":"Mol Diagn Ther"},{"issue":"15 Pt 1","key":"1053_CR12","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-07-0122","volume":"13","author":"S Badve","year":"2007","unstructured":"Badve S, et al. FOXA1 expression in breast cancer\u2013correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415\u201321.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1053_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"issue":"3","key":"1053_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-013-2699-3","volume":"141","author":"G Ciriello","year":"2013","unstructured":"Ciriello G, et al. The molecular diversity of luminal A breast tumors. Breast Cancer Res Treat. 2013;141(3):409\u201320.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1053_CR15","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1053_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","volume":"6","author":"JA Sparano","year":"2020","unstructured":"Sparano JA, et al. Clinical outcomes in early breast cancer with a high 21-Gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2020;6(3):367\u201374.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1053_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","volume":"27","author":"I Noordhoek","year":"2021","unstructured":"Noordhoek I, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR(+) Early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021;27(1):311\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1053_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mds334","volume":"24","author":"P Dubsky","year":"2013","unstructured":"Dubsky P, et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24(3):640\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"1053_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus R, et al. Molecular drivers of oncotype DX, Prosigna, EndoPredict, and the breast cancer index: A transatac study. J Clin Oncol. 2021;39(2):126\u201335.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1053_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13058-016-0724-2","volume":"18","author":"D Netanely","year":"2016","unstructured":"Netanely D, et al. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. Breast Cancer Res. 2016;18(1):74.","journal-title":"Breast Cancer Res"},{"key":"1053_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-019-0116-8","volume":"5","author":"P Poudel","year":"2019","unstructured":"Poudel P, et al. Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. NPJ Breast Cancer. 2019;5:21.","journal-title":"NPJ Breast Cancer"},{"issue":"7403","key":"1053_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","volume":"486","author":"PJ Stephens","year":"2012","unstructured":"Stephens PJ, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400\u20134.","journal-title":"Nature"},{"issue":"5","key":"1053_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/apm.12920","volume":"127","author":"M Rossing","year":"2019","unstructured":"Rossing M, et al. Whole genome sequencing of breast cancer. APMIS. 2019;127(5):303\u201315.","journal-title":"APMIS"},{"issue":"15","key":"1053_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"key":"1053_CR25","doi-asserted-by":"crossref","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1).","DOI":"10.14806\/ej.17.1.200"},{"issue":"5","key":"1053_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589\u201395.","journal-title":"Bioinformatics"},{"issue":"16","key":"1053_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, et al. The sequence Alignment\/Map format and samtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics"},{"issue":"3","key":"1053_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568\u201376.","journal-title":"Genome Res"},{"issue":"16","key":"1053_CR29","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1053_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, et al. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"70","key":"1053_CR31","doi-asserted-by":"publisher","first-page":"33337","DOI":"10.18632\/oncotarget.26071","volume":"9","author":"C Kikutake","year":"2018","unstructured":"Kikutake C, et al. Intratumor heterogeneity of HMCN1 mutant alleles associated with poor prognosis in patients with breast cancer. Oncotarget. 2018;9(70):33337\u201347.","journal-title":"Oncotarget"},{"key":"1053_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-017-0308-x","volume":"101","author":"C Peng","year":"2017","unstructured":"Peng C, et al. Enhanced identification of potential pleiotropic genetic variants for bone mineral density and breast cancer. Calcif Tissue Int. 2017;101:489\u2013500.","journal-title":"Calcif Tissue Int"},{"key":"1053_CR33","doi-asserted-by":"publisher","first-page":"1003957","DOI":"10.3389\/fonc.2022.1003957","volume":"12","author":"T Guan","year":"2022","unstructured":"Guan T, et al. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma. Front Oncol. 2022;12:1003957.","journal-title":"Front Oncol"},{"key":"1053_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.canlet.2021.07.039","volume":"519","author":"D McGarry","year":"2021","unstructured":"McGarry D, et al. MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Lett. 2021;519:226\u201336.","journal-title":"Cancer Lett"},{"key":"1053_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00018-023-04810-y","volume":"80","author":"Y Li","year":"2023","unstructured":"Li Y, et al. G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression. Cell Mol Life Sci. 2023;80:165.","journal-title":"Cell Mol Life Sci"},{"key":"1053_CR36","doi-asserted-by":"publisher","first-page":"p266","DOI":"10.1186\/s12935-021-01976-y","volume":"21","author":"E Sajjadi","year":"2021","unstructured":"Sajjadi E, et al. Mismatch repair-deficient hormone receptor-positive breast cancers: biology and pathological characterization. Cancer Cell Int. 2021;21:p266.","journal-title":"Cancer Cell Int"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01053-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:56:51Z","timestamp":1762873011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-025-01053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1053"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01053-6","relation":{},"ISSN":["1472-6750"],"issn-type":[{"type":"electronic","value":"1472-6750"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Approval No. 2024\u2009\u2212\u20091001). This study was conducted in compliance with the Declaration of Helsinki. Because this study was a retrospective analysis of archived, de\u2011identified FFPE tumor samples and the associated clinical data, the Ethics Committee of Sir Run Run Shaw Hospital waived the requirement for written informed consent in accordance with the relevant national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}